BioPlus Acquisition Corp.
"We are focused on the life sciences industry across the US, EU, Israel and Australasia(1), where we have deep clinical, regulatory, operational and commercial expertise. Furthermore, we believe our management team and board’s extensive experience positions us to be therapeutic area agnostic. We plan to identify and assess target assets leading to an efficient pathway to a merger."
Ross Haghighat, CEO & CFO
(1) Excluding China, Hong Kong and Macau
“SPACs with operators at the helm outperformed others”
“Operator-led SPACs are more focused and better governed”
Recent News and Announcements
New York, NY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global...